Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a $110 price target.
August 05, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Biomarin Pharmaceutical and maintained a $110 price target.
The reiteration of an Overweight rating and a maintained price target of $110 by a reputable analyst is likely to positively influence investor sentiment and potentially drive short-term price appreciation for Biomarin Pharmaceutical.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100